Keywords: b-ms, gains, rights, eisai, antifungal, japan, licensed

B-MS Gains Rights For Eisai Antifungal

Article | 23 December 1996

Eisai of Japan has licensed its oral broad-spectrum antifungal triazole, ER-30346, to US company Bristol-Myers Squibb, which gets exclusive worldwide ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Eisai

Bristol-Myers Squibb

Go to company listing

Related Drugs

Nystatin

Zerit

Stavudine

Cefprozil

Cefzil

Go to drug listing